MARKET

AFMD

AFMD

Affimed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.010
-0.220
-5.20%
Opening 14:28 07/14 EDT
OPEN
4.260
PREV CLOSE
4.230
HIGH
4.345
LOW
3.900
VOLUME
1.36M
TURNOVER
--
52 WEEK HIGH
4.910
52 WEEK LOW
1.420
MARKET CAP
336.24M
P/E (TTM)
-5.7590
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AFMD stock price target is 7.11 with a high estimate of 10.01 and a low estimate of 5.51.

EPS

AFMD News

More
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 4d ago
Affimed Announces Annual General Meeting of Shareholders
Heidelberg, Germany, July 10, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight.
GlobeNewswire · 4d ago
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 07/02 12:21
Will Affimed Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor of Affimed
Zacks · 06/30 15:03
Implied Volatility Surging for Affimed (AFMD) Stock Options
Investors need to pay close attention to Affimed (AFMD) stock based on the movements in the options market lately.
Zacks · 06/29 12:43
Hedge Funds Have Never Been This Bullish On Affimed NV (AFMD)
Insider Monkey · 06/28 22:57
Affimed N.V. (NASDAQ:AFMD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Simply Wall St. · 06/25 11:02
SVB Leerink Maintains Outperform on Affimed, Raises Price Target to $8
SVB Leerink maintains Affimed (NASDAQ:AFMD) with a Outperform and raises the price target from $7 to $8.
Benzinga · 06/24 10:31

Industry

Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.17%

Hot Stocks

Symbol
Price
%Change

About AFMD

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
More

Webull offers kinds of Affimed NV stock information, including NASDAQ:AFMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AFMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AFMD stock methods without spending real money on the virtual paper trading platform.